Study Data Show Better Outcomes With Access Vascular’s Hydrophilic Midline Catheter

New real-world data reinforces the significant improvements in midline catheter outcomes linked to Access Vascular Inc.’s proprietary hydrophilic biomaterial (HBM).

The study was independently designed and conducted by an acute care hospital in Montana and evaluated outcomes across 288 patients. It compared a conventional chlorhexidine gluconate (CHG)-coated polyurethane catheter to Access Vascular’s HydroMID HBM-based catheter.

Building on previously shared conclusions, the latest expanded data show:

• A 75% lower complication rate: HydroMID exhibited a 5.3% complication rate, compared with 21.8% for CHG polyurethane.
• Greater therapy completion: 95% of HydroMID patients completed therapy with the original line in place, compared to just 80% for CHG polyurethane.
• Extended dwell time: HydroMID remained in place nearly 40% longer than CHG polyurethane catheters.

“With more than 125 catheters in each study arm, these findings add to the growing body of evidence that our hydrophilic biomaterial platform delivers tangible benefits where it matters most: improved outcomes for patients,” Access Vascular CEO Jim Biggins said. “Fewer complications, longer dwell times, and higher rates of therapy completion all support a safer, more efficient experience for patients and providers alike.”

Unlike traditional polyurethane catheters, AVI’s devices are constructed from MIMIX, a proprietary hydrogel-based material designed to reduce thrombus formation and bacterial adhesion. This fundamental material change targets the root causes of vascular access device failure.

“Concerns relating to frequent complications with our previous midline device kept growing. We felt defeated in our efforts to get our patients to the end of their therapy – we knew we could do better for them,” said Kelsey Pearson, R.N., VA-BC at Benefis Hospital. “We have noticed a significant improvement in our outcomes and provided a better patient experience since switching to the HydroMID catheter.”

Access Vascular Inc. engineers devices from a fundamentally better material. The MIMIX hydrogel platform is designed to reduce the complications associated with traditional catheters, helping clinicians keep lines in place, improving the patient experience and delivering value to hospitals.